Akanda

Akanda Financing Cash Flow

The Net Financing Cash Flow of Akanda (AKAN) as of Oct 28, 2026 is 11.68 M USD. In the previous year, Net Financing Cash Flow was 8.99 M USD — a change of 29.91% (higher).

Financing Cash Flow

11.68 MUSD

YoY

29.91%

Last updated:

Net Financing Cash Flow of Akanda is 2025 11.68 M USD. Net Financing Cash Flow of Akanda was 2024 8.99 M USD. It decreases by 29.91% higher compared to the previous year.

The Akanda Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2019
2.12 M USD
Jan 1, 2020
1.03 M USD
Jan 1, 2021
11.24 M USD
Jan 1, 2022
14.14 M USD
Jan 1, 2023
1.49 M USD
Jan 1, 2024
8.99 M USD
Jan 1, 2025
11.68 M USD
The Akanda Financing Cash Flow history
YEARFinancing Cash FlowYoY
11.68 MUSD+29.91%
8.99 MUSD+504.71%
1.49 MUSD-89.49%
14.14 MUSD+25.84%
11.24 MUSD+987.17%
1.03 MUSD-51.17%
2.12 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Net Financing Cash Flow of Akanda is 11.68 M USD in 2025.

Net Financing Cash Flow of Akanda changed from 8.99 M USD to 11.68 M USD, representing a 29.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Akanda since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Akanda historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Akanda

All Key Metrics — Akanda